Vascular endothelial cell growth factor antagonists and uses thereof
AssigneeGenentech, Inc.
InventorsNicholas Van Bruggen, Napoleone Ferrara
Life of this patent
Estimating the term…
Abstract
The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.
Claims16
A method of reducing cerebral edema mediated by VEGF and associated with a non-neoplastic disease, condition, or stimuli in a mammal in need thereof, comprising administering to said mammal an effective amount of an hVEGF antagonist, wherein said hVEGF antagonist interferes with the binding of hVEGF to a cellular receptor, and wherein said hVEGF antagonist comprises an anti-hVEGF antibody or an hVEGF-binding fragment thereof.
A method of treating ischemic stroke in a mammal in need thereof, comprising administering to said mammal an effective amount of an hVEGF antagonist, wherein said hVEGF antagonist interferes with the binding of hVEGF to a cellular receptor, and wherein said hVEGF antagonist comprises an anti-hVEGF antibody or an hVEGF-binding fragment thereof.
Dependencies are inferred from the claim text.